Huntington's Disease

IN: the path from Huntington's disease biology to therapy - the HTT gene mutation, mutant huntingtin protein, neurodegeneration, huntingtin-lowering and other drug modalities, clinical trials, biomarkers, regulatory milestones, patient outcomes, and the companies developing HD treatments. OUT: unrelated neurodegenerative diseases unless directly comparative, general biotech market commentary, single-name stock trading calls, and non-therapeutic lifestyle or fundraising stories.

This causal map links 47 factors across 64 relationships. The strongest:

• Htt Gene Mutation enables Mutant Huntingtin Protein. Confidence: 80%.
• Antisense Oligonucleotide decreases Mutant Huntingtin Protein. Confidence: 80%.
• Gene Therapy enables Uniqure. Confidence: 66%.
• Htt Lowering Therapy decreases Mutant Huntingtin Protein. Confidence: 61%.
• Gene Therapy enables Fda Approval. Confidence: 47%.
• Allele Specific Crispr Cas9 prevents Mutant Huntingtin Protein. Confidence: 45%.
• Htt Lowering Therapy decreases Neurodegeneration. Confidence: 45%.
• Htt Lowering Therapy increases Motor Coordination. Confidence: 45%.
• Htt Lowering Therapy increases Survival. Confidence: 45%.
• Allele Specific Crispr Cas9 enables Htt Lowering Therapy. Confidence: 44%.
• Cet Modification increases Antisense Oligonucleotide. Confidence: 44%.
• Intrathecal Administration enables Antisense Oligonucleotide Cns Distribution. Confidence: 44%.
• Blood Brain Barrier prevents Antisense Oligonucleotide Cns Distribution. Confidence: 44%.
• Mutant Huntingtin Protein Aggregates enables Neuronal Intranuclear Inclusions. Confidence: 43%.
• Phosphorothioate Backbone Modification increases Plasma Protein Binding. Confidence: 43%.
• Sugar 2 Prime Position Modification increases Antisense Oligonucleotide Potency. Confidence: 43%.
• Sky 0515 decreases Mutant Huntingtin Protein. Confidence: 43%.
• Somatic Cag Expansion increases Neurodegeneration. Confidence: 43%.
• Caspase Cleavage Of Htt increases Mutant Huntingtin Protein Aggregates. Confidence: 43%.
• Plasma Protein Binding increases Tissue Bioavailability. Confidence: 43%.
• Amt 130 Gene Therapy enables Fda Approval. Confidence: 42%.
• Fan1 prevents Somatic Cag Expansion. Confidence: 42%.
• Htt Lowering Therapy decreases Neurofilament Light. Confidence: 42%.
• Msh3 increases Somatic Cag Expansion. Confidence: 42%.
• Msh3 Lowering Therapy decreases Somatic Cag Expansion. Confidence: 42%.
• Neurodegeneration increases Neurofilament Light. Confidence: 42%.
• Wild Type Huntingtin Protein enables Neurodegeneration. Confidence: 42%.
• Systemic Aav Dose increases Neuroinflammation. Confidence: 41%.
• Htt Gene Mutation increases Mutant Huntingtin Protein. Confidence: 41%.
• Gene Therapy decreases Neurodegeneration. Confidence: 41%.
• Cns Targeted Aav Delivery increases Transgene Expression. Confidence: 41%.
• Neurodegeneration correlates with Mutant Huntingtin Protein. Confidence: 39%.
• Neuroinflammation decreases Transgene Expression. Confidence: 38%.
• Fda Approval enables Uniqure. Confidence: 37%.
• Branaplam Safety Concerns prevents Branaplam. Confidence: 36%.
• Votoplam decreases Mutant Huntingtin Protein. Confidence: 36%.
• Branaplam decreases Mutant Huntingtin Protein. Confidence: 36%.
• Sky 0515 Dose Level decreases Mutant Huntingtin Protein. Confidence: 32%.
• Mutant Huntingtin Protein triggers Neurodegeneration. Confidence: 32%.
• Fda Dispute Resolution enables Fda Approval. Confidence: 30%.
• Fda Regulatory U Turn enables Uniqure. Confidence: 30%.
• Uniqure enables Fda Approval. Confidence: 30%.
• Fda Dispute Resolution enables Uniqure. Confidence: 29%.
• Fda Regulatory U Turn enables Gene Therapy. Confidence: 28%.
• Antisense Oligonucleotide decreases Neurodegeneration. Confidence: 25%.
• Gene Therapy decreases Mutant Huntingtin Protein. Confidence: 25%.
• Gene Therapy enables Htt Lowering Therapy. Confidence: 25%.
• Amt 130 Gene Therapy decreases Mutant Huntingtin Protein. Confidence: 21%.
• Tiny Cell Tunnels enables Mutant Huntingtin Protein Spread. Confidence: 21%.
• Gene Therapy triggers Fda Approval. Confidence: 20%.